An Overview of Emerging Immunotargets of Genitourinary Tumors

Author(s): Rodolfo Montironi, Matteo Santoni, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana, Holger Moch, Marina Scarpelli

Journal Name: Current Drug Targets

Volume 17 , Issue 7 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Emerging immunotherapies targeting immune checkpoints and tumor associated antigens are leading to important clinical advances and providing a new weapon in patients with prostate (PCa) and bladder cancer (BC) and, in particular, with renal cell carcinoma (RCC). The possibility to integrate these agents in the current therapeutic scenario or genitourinary tumors, both in sequential or combined approaches, relies on a more profound comprehension of the protumorigenic activity of the immune system and of the mechanisms of cancer-related immunosuppression. In this regards, neutrophils, T and B lymphocytes and tumor-associated macrophages (TAMs) are implicated in the pathogenesis, progression and development of drug resistance in genitourinary tumors. This review is an overview on the recent insights concerning the role of immune cells in this context.

Keywords: Genitourinary tumors, immunotherapy, lymphocytes, macrophages, neutrophils.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [750 - 756]
Pages: 7
DOI: 10.2174/1389450117666151209144649
Price: $65

Article Metrics

PDF: 53
PRC: 1